Applied Quantum Chemistry for Oncology
Triplet State Technology LLC (TST) is a Washington State licensed LLC. The company’s primary office is in Longview, WA. The company maintains a research office in Los Angeles, CA near the UCLA campus. TST was formed to research and engineer applications of patents solely owned by Dr. Robert Sandstrom, company founder. The patents address methods for modifying the reaction dynamics of free radicals in tumor tissue.
The clinical efficacy of radiation therapy is the direct result of radiation-induced free radicals. Free radicals generated in the process of radiation therapy are generally short-lived and their half-life largely determined by recombination events. The current TST device is designed to work specifically with commonly employed medical linear accelerators treating in the X-ray photon mode. Conformational radiation methods localize the radiation to specific anatomic sites.
In the course of developing and designing the experimental protocols, TST worked to design and build a proprietary device to expose cell cultures and mice with a magnetic field of specific field strength and geometry. The Magnetic Field Generator System (MFGS), used as an adjunct to radiation therapy provides a uniform magnetic field into which the treatment target may be placed. This is called the Sandstrom method. The Sandstrom method predicts a quantum effect which results from the presence of free radicals in a selective structured magnetic field. The presence of a magnetic field induces the generation of free radicals, limiting recombination and increasing the local concentration of non-recombinant free radicals, which act to selectively target and destroy tumor cells.
TST works closely with the UCLA Department of Radiation Oncology headed by Professor Michael Steinberg MD and includes Daniel Low PhD, William McBride PhD, and Kei Iwamoto PhD. Daniel Low PhD and Kei Iwamoto PhD have entered into collaboration with TST and Dr. Sandstrom to investigate the effect of a structured magnetic field of determinate field strength in conjunction with X-ray photon radiation on tumor cell cultures and implanted tumors in mice.
A series of experimental efforts demonstrated the effect in human glioblastoma cell cultures and in Lewis Lung carcinoma cell cultures. Lewis Lung carcinoma implants in syngeneic C57BL/6 mice demonstrated improved response to radiation therapy when the structured magnetic field was added to the treatment protocol. A level of cell growth inhibition in animal studies versus radiation alone suggested a benefit of 38%, which translated into higher tumor cell kill when the magnetic field was included.
In the course of developing and designing the experimental protocols, TST worked to design and build a proprietary device to expose cell cultures and mice with a magnetic field of specific field strength and geometry. TST and the UCLA research team have demonstrated that there is no demonstrable histologic tissue or hematologic injury in normal tissue of mice ascribable to the magnetic field in treated or control animals.
Testing at Intertek, Inc. in Irvine, CA was completed in December 2022.